Mirum Pharmaceuticals, Inc.MIRMEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Mirum Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare, debilitating liver diseases that have high unmet medical needs, serving both pediatric and adult patient groups across North America, Europe and other global regions.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| S.S. OR | 9.40% | 4.5M | ▼ -1.20pp | 2024-11-14 |
| Frazier Life Sciences IX, L.P. | 7.70% | 3.6M | — | 2023-09-05 |
| Eventide Asset Management, LLC | 7.22% | 3.4M | ▲ +1.44pp | 2024-11-14 |
| BlackRock, Inc. | 7.10% | 3.4M | flat | 2024-11-12 |
| New Enterprise Associates 16, L.P. | 5.80% | 2.2M | — | 2023-06-23 |
| The Vanguard Group | 5.31% | 2.5M | — | 2024-02-13 |
| Biotechnology Value Fund, L.P. | 3.30% | 1.6M | ▼ -1.70pp | 2024-11-14 |
| OF ABOVE PERSONS | 0.00% | 604.7M | — | 2023-05-03 |
Insider Transactions
Net 90d: −$7.64M · buys $0 / sells $7.64MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-15 | Saira Ramasastry | Director | Option exercise | 2.0K | $23.51 | $47.0K |
| 2026-04-15 | Saira Ramasastry | Director | Sell (open market) | 2.0K | $96.90 | $193.8K |
| 2026-03-16 | Saira Ramasastry | Director | Option exercise | 2.0K | $23.51 | $47.0K |
| 2026-03-16 | Saira Ramasastry | Director | Sell (open market) | 2.0K | $90.76 | $181.5K |
| 2026-03-16 | Peter Radovich | PRESIDENT AND COO | Sell (open market) | 16.5K | $91.98 | $1.52M |
| 2026-03-16 | Joanne Quan | CHIEF MEDICAL OFFICER | Sell (open market) | 7.3K | $91.98 | $670.2K |
| 2026-03-16 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell (open market) | 4.7K | $91.98 | $435.2K |
| 2026-03-16 | BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER | Sell (open market) | 7.3K | $91.98 | $670.2K |
| 2026-03-16 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | Sell (open market) | 41.0K | $91.98 | $3.77M |
| 2026-03-15 | Peter Radovich | PRESIDENT AND COO | Option exercise | 7.2K | — | — |
1–10 of 20
Page 1 / 2